SAN DIEGO, April 15, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced its attendance, physician presentations, and related events at the 2015 American Society of Cataract and Refractive Surgery (ASCRS) in San Diego, CA, April 17-21.
Imprimis will host an informational Go Dropless™ and LessDrops™ Reception on Saturday, April 18, 5:30-8:30 pm at the Hard Rock Hotel. Mark L. Baum, CEO of Imprimis Pharmaceuticals, will convey the company's vision and the continuing success stemming from the Go Dropless campaign launched in April 2014 and recent launch of the LessDrops campaign. Additionally, a panel of current prescribers will share their experience and expertise with the proprietary formulations and how they have incorporated them into their surgical practices. The faculty members will include: Ephraim Atwal, MD (Cheektowaga, NY), Bret Fisher, MD (Panama City, FL), Damien Goldberg, MD (Torrance, CA), Tyrie Jenkins, MD, (Honolulu, HI), Jeffrey Liegner, MD (Sparta, NJ), James Loden, MD (Goodlettsville, TN), Ahad Mahootchi, MD (Zephyrhills, FL), Sydney Tyson, MD (Vineland, NJ), and William Wiley, MD (Avon, OH).
Mark L. Baum, CEO of Imprimis stated, "It is a privilege to participate at the ASCRS Symposium and Congress taking place in our home town of San Diego. Interest in our innovative ophthalmic drug formulations continues to grow and we look forward to visiting with and hosting our friends and customers in the ophthalmology community. This venue also provides us with the opportunity to share the experience of our Dropless Therapy injectable and Combination Drop Therapy topical formations with new physicians and their staffs who have not yet heard our message."
Dropless Therapy will be presented at ASCRS in several sessions:
Sunday, April 19, 10:48-11:58 pm: Controversies in Anterior Segment Surgery: "Dropless Drug Delivery—Should We Be Transitioning to This Now?" - Eric D. Donnenfield, MD, San Diego Convention Center, Room 5A.
Sunday, April 19, 3:00-4:30 pm: Cataract Dilemmas and Controversies: "Intracameral Antibiotics/Topical Versus Dropless Cataract Surgery (Safety and Cost/Efficiencies)" - David F. Chang, MD, Kent Stiverson, MD, andRobert J. Weinstock, MD, San Diego Convention Center, Room 6A.
Monday, April 20, 1:00-2:30 pm: Course 20-305: "Dropless Cataract Surgery: Transzonular Placement of Antibiotic and Steroid for Postoperative Prophylaxis after Cataract Surgery" - M. Stewart Galloway, MD, James S. Lewis, MD, Jeffrey T. Liegner, MD, Richard Lindstrom, MD, andAhad Mahootchi, MD, San Diego Convention Center, Room 6F.
Monday, April 20, 3:00-4:35 pm: Cataract Medications: "Cystoid Macular Edema Rates with Intravitreal Transzonular Antibiotic/Steroid Prophylaxis," - M. Stewart Galloway, MD and Jeffrey T. Liegner, MD, San Diego Convention Center, Room 1B.
Both Dropless Therapy and our Combination Drop Therapy will be discussed during Dr. Robert H. Osher's annual "New Technologies" symposium:
Monday, April 20, 3:00-4:30 pm: Symposium: "New Technologies – What Do I Really Need?" - Robert H. Osher, MD, San Diego Convention Center, Room 6A.
In addition, ASCRS will hold a 2015 FDA Symposium, Current FDA Issues: Update on Drug Compounding and the 21st Century Cures Initiative, consisting of two panels: a panel focusing on the drug compounding issue and its impact on ophthalmology which will include Mark L. Baum and a second panel highlighting the 21st Century Cures Initiative with a particular focus on the steps that can be taken to ensure that the drug and device approval process is fostering innovation in America. The FDA Symposium will take place on Sunday, April 19 from 8:00-9:30 am, San Diego Convention Center, Room 6D.
Additional information about Imprimis and its patent-pending, innovative treatment options and the events at ASCRS will be available to conference attendees at the Imprimis Booth #414.
ABOUT THE AMERICAN SOCIETY OF CATARACT AND REFRACTICE SURGERY
The American Society of Cataract and Refractive Surgery is an international, educational society with more than 9,000 members. Its mission is to advance the art and science of ophthalmic surgery and the knowledge and skills of ophthalmic surgeons by providing clinical and practice management education and by working with patients, government, and the medical community to promote the delivery and advancement of high-quality eye care.
Since its founding in 1974, ASCRS has led the field through significant advances in technology and clinical science through its educational programs, publications and on-line resources. ASCRS has become the surgeons' primary source of up-to-date clinical information, published research, and regulatory information affecting the practice of medicine.
ABOUT IMPRIMIS' OPHTHALMIC FORMULATIONS
Imprimis acquired the intellectual property for its patent-pending Dropless Therapy™ and other ophthalmic formulations in August 2013. The company's SSP Technology™ allows for increased solubility of active pharmaceutical ingredients, creating small, uniform particle sizes which enable functionality as an injectable or use as a topical eye drop.
Imprimis provides proprietary compounded antibiotic and steroid formulations, Tri-Moxi and Tri-Moxi-Vanc, available in single, injectable intraocular doses administered during ocular surgery. The Go Dropless™ educational campaign was launched in April 2014 to inform ophthalmologists about Dropless Therapy™ opportunities and the unique injectable compounded formulations that can virtually eliminate the need for eye drops following ocular surgery. Since launch, Dropless Therapy compounded formulations have been prescribed for individual patients and administered in over 35,000 eye surgeries where, as a result of the surgery, there is inflammation and a chance for post-operative infection. Prescribers of Dropless Therapy have been reporting on its advantages, which include improved patient compliance, reduced costs to patients, and decreased post-operative physician care. More information is available at www.GoDropless.com.
In February 2015, Imprimis launched a portfolio of Combination Drop Therapy topical formulations. This campaign, branded LessDrops™, has the promise of requiring up to 50% fewer drops to be administered by patients and may provide a significant cost savings of up to 75% compared to current traditional post-surgery eye drop treatments. The initial offering includes proprietary Tri-Moxi and Pred-Moxi formulations as combination topical eye drops for patients following LASIK, cataract, and other ocular surgeries. For more information, please visit www.LessDrops.com.
All Imprimis formulations may be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis' business is focused on its proprietary ophthalmology and urology drug formulations. The company's pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis. For more information about Imprimis, please visit the company's corporate website at www.ImprimisPharma.com; ophthalmology business websites at www.GoDropless.com and www.LessDrops.com; and urology business website at www.DefeatIC.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.